Page 33 - Read Online
P. 33

Watanabe. Vessel Plus 2020;4:4  I  http://dx.doi.org/10.20517/2574-1209.2019.27                                                      Page 7 of 10

               DECLARATIONS
               Acknowledgments
               The author thanks Ms. Yui Takahashi for her technical assistance.


               Authors’ contributions
               The author contributed solely to the article.

               Availability of data and materials
               Not applicable.

               Financial support and sponsorship
               This work was supported in part by a Grant-in-Aid for Scientific Research (C) (17K08993 to T.W.) from the
               Japan Society for the Promotion of Science.


               Conflicts of interest
               The author declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2020.


               REFERENCES
               1.   Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global
                   burden of atherothrombotic disease. Circ Res 2016;118:535-46.
               2.   Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des
                   2012;18:4266-88.
               3.   Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2014;114:1852-66.
               4.   Jian X, Liu Y, Zhao Z, Zhao L, Wang D, et al. The role of traditional Chinese medicine in the treatment of atherosclerosis through the
                   regulation of macrophage activity. Biomed Pharmacother 2019;118:109375.
               5.   Malekmohammad K, Sewell RDE, Rafieian-Kopaei M. Antioxidants and atherosclerosis: mechanistic aspects. Biomolecules 2019;9:301.
               6.   Singh S. Herbal approach for management of atherosclerosis: a review. Curr Atheroscler Rep 2019;21:12.
               7.   Wang C, Niimi M, Watanabe T, Wang Y, Liang J, et al. Treatment of atherosclerosis by traditional Chinese medicine: questions and
                   quandaries. Atherosclerosis 2018;277:136-44.
               8.   Gholipour S, Sewell RDE, Lorigooini Z, Rafieian-Kopaei M. Medicinal plants and atherosclerosis: a review on molecular aspects. Curr
                   Pharm Des 2018;24:3123-31.
               9.   Sedighi M, Bahmani M, Asgary S, Beyranvand F, Rafieian-Kopaei M. A review of plant-based compounds and medicinal plants effective
                   on atherosclerosis. J Res Med Sci 2017;22:30.
               10.  Takahashi Y, Watanabe R, Sato Y, Ozawa N, Kojima M, et al. Novel phytopeptide osmotin mimics preventive effects of adiponectin on
                   vascular inflammation and atherosclerosis. Metabolism 2018;83:128-38.
               11.  Liu J, Sui H, Zhao J, Wang Y. Osmotin protects H9c2 cells from stimulated ischemia-reperfusion injury through AdipoR1/PI3K/AKT
                   signaling pathway. Front Physiol 2017;8:611.
               12.  Singh NK, Bracker CA, Hasegawa PM, Handa AK, Buckel S, et al. Characterization of osmotin: a thaumatin-like protein associated with
                   osmotic adaptation in plant cells. Plant Physiol 1987;85:529-36.
               13.  Anil Kumar S, Hima Kumari P, Shravan Kumar G, Mohanalatha C, Kavi Kishor PB. Osmotin: a plant sentinel and a possible agonist of
                   mammalian adiponectin. Front Plant Sci 2015;6:163.
               14.  Viktorova J, Krasny L, Kamlar M, Novakova M, Mackova M, et al. Osmotin, a pathogenesis-related protein. Curr Protein Pept Sci
                   2012;13:672-81.
               15.  Liu D, Narasimhan ML, Xu Y, Raghothama KG, Hasegawa PM, et al. Fine structure and function of the osmotin gene promoter. Plant
   28   29   30   31   32   33   34   35   36   37   38